PTPI Petros Pharmaceuticals
- 0.6100
- -0.0035-0.57%
- 0.6000
- -0.0100-1.64%
Petros Pharmaceuticals News
Petros Pharmaceuticals | EFFECT: Others
Petros Pharmaceuticals | 10-Q: Quarterly report
Petros Pharmaceuticals | S-3: Registration statement for specified transactions by certain issuers
Petros Pharmaceuticals | 10-K: Annual report
Petros Pharmaceuticals | 8-K: Current report
Petros Pharmaceuticals | SC 13G: Statement of acquisition of beneficial ownership by individuals-Ayrton Capital LLC(9.9%),Alto Opportunity Master Fund, SPC – Segregated Master Portfolio B(9.9%)
Petros Pharmaceuticals | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Mitchell P. Kopin(6.6%),Daniel B. Asher(6.6%), etc.
Petros Pharmaceuticals | 8-K: Current report
Petros Pharmaceuticals | 8-K: Current report
Petros Pharmaceuticals | 8-K: Current report
Petros Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Bernstein Bruce
Petros Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Boctor Fady
Petros Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director WALKER WAYNE REMELL
Petros Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Arnold Mitchell
Petros Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Silverman Joshua
Petros Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Bradley Greg
Petros Pharmaceuticals | ARS: Annual Report to Security Holders
Petros Pharmaceuticals | DEF 14A: Definitive information statements
Petros Pharmaceuticals: Q3 2023 Earnings Report
Petros Pharmaceuticals | NT 10-Q: Notice under Rule 12b25 of inability to timely file all or part of a form 10-Q or 10-QSB
Analysis
Price Target
No Data
